Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGM NASDAQ:NLTX NASDAQ:SANA NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMBGM Group$8.21+4.5%$8.44$6.22▼$17.17$798.19M1.2646,412 shs234,623 shsNLTXNeoleukin Therapeutics$19.00-5.4%$20.72$2.03▼$14.36$178.56M1.1150,104 shs123,069 shsSANASana Biotechnology$3.10-4.0%$3.72$1.26▼$7.30$737.21M1.885.75 million shs2.30 million shsVIRVir Biotechnology$4.86+1.5%$5.06$4.16▼$14.45$675.13M1.281.57 million shs664,430 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMBGM Group+6.50%+7.23%+3.83%-37.87%+21.30%NLTXNeoleukin Therapeutics0.00%-4.76%-7.36%+0.16%-54.71%SANASana Biotechnology+0.31%+7.67%-3.00%+14.95%-27.74%VIRVir Biotechnology-4.20%-7.71%+5.97%-6.08%-40.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMBGM Group$8.21+4.5%$8.44$6.22▼$17.17$798.19M1.2646,412 shs234,623 shsNLTXNeoleukin Therapeutics$19.00-5.4%$20.72$2.03▼$14.36$178.56M1.1150,104 shs123,069 shsSANASana Biotechnology$3.10-4.0%$3.72$1.26▼$7.30$737.21M1.885.75 million shs2.30 million shsVIRVir Biotechnology$4.86+1.5%$5.06$4.16▼$14.45$675.13M1.281.57 million shs664,430 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMBGM Group+6.50%+7.23%+3.83%-37.87%+21.30%NLTXNeoleukin Therapeutics0.00%-4.76%-7.36%+0.16%-54.71%SANASana Biotechnology+0.31%+7.67%-3.00%+14.95%-27.74%VIRVir Biotechnology-4.20%-7.71%+5.97%-6.08%-40.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGMBGM Group 0.00N/AN/AN/ANLTXNeoleukin Therapeutics 0.00N/AN/AN/ASANASana Biotechnology 3.00Buy$8.00158.06% UpsideVIRVir Biotechnology 2.90Moderate Buy$17.30255.97% UpsideCurrent Analyst Ratings BreakdownLatest NLTX, VIR, BGM, and SANA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025VIRVir BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.009/3/2025VIRVir BiotechnologyEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$12.008/27/2025VIRVir BiotechnologyBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$12.00 ➝ $14.007/11/2025VIRVir BiotechnologyRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform7/11/2025VIRVir BiotechnologyRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy$12.007/3/2025SANASana BiotechnologyMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$12.006/24/2025SANASana BiotechnologyJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$5.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGMBGM Group$26.85M29.73N/AN/A$7.34 per share1.12NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ASANASana BiotechnologyN/AN/AN/AN/A$1.12 per shareN/AVIRVir Biotechnology$14.39M46.91N/AN/A$8.35 per share0.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGMBGM Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/ANLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ASANASana Biotechnology-$266.76M-$1.06N/AN/AN/AN/A-91.96%-43.07%11/14/2025 (Estimated)VIRVir Biotechnology-$521.96M-$4.00N/AN/AN/A-2,895.94%-50.22%-40.78%10/30/2025 (Estimated)Latest NLTX, VIR, BGM, and SANA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025SANASana Biotechnology-$0.20-$0.16+$0.04-$0.39N/AN/A8/6/2025Q2 2025VIRVir Biotechnology-$0.72-$0.80-$0.08-$0.80$2.38 million$1.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGMBGM GroupN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGMBGM GroupN/A1.821.45NLTXNeoleukin TherapeuticsN/A15.3315.33SANASana BiotechnologyN/A2.472.47VIRVir BiotechnologyN/A7.017.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGMBGM GroupN/ANLTXNeoleukin Therapeutics52.37%SANASana Biotechnology88.23%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipBGMBGM Group58.66%NLTXNeoleukin Therapeutics1.58%SANASana Biotechnology31.10%VIRVir Biotechnology16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGMBGM Group29897.22 million40.19 millionN/ANLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataSANASana Biotechnology380237.81 million163.85 millionOptionableVIRVir Biotechnology580138.92 million116.69 millionOptionableNLTX, VIR, BGM, and SANA HeadlinesRecent News About These CompaniesHC Wainwright Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR)4 hours ago | marketbeat.comVir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript5 hours ago | seekingalpha.com84,398 Shares in Vir Biotechnology, Inc. $VIR Purchased by Cinctive Capital Management LPSeptember 8, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading Down 6% on Insider SellingSeptember 6, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Now Covered by Analysts at Evercore ISISeptember 6, 2025 | americanbankingnews.comVicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) StockSeptember 5, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Stock Price Up 8% - Here's WhySeptember 5, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Now Covered by Evercore ISISeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Purchases 185,933 Shares of Vir Biotechnology, Inc. $VIRSeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Sells 542,000 Shares of Vir Biotechnology, Inc. $VIRSeptember 4, 2025 | marketbeat.comEvercore ISI Group Initiates Coverage of Vir Biotechnology (VIR) with Outperform RecommendationSeptember 3, 2025 | msn.comThe Play On Vir BiotechnologySeptember 3, 2025 | seekingalpha.comVir Biotechnology initiated with an Outperform at Evercore ISISeptember 3, 2025 | msn.comVir Biotechnology, Inc. $VIR Shares Bought by Russell Investments Group Ltd.September 2, 2025 | marketbeat.comWalleye Capital LLC Sells 183,494 Shares of Vir Biotechnology, Inc. $VIRSeptember 1, 2025 | marketbeat.comNuveen LLC Takes $2.32 Million Position in Vir Biotechnology, Inc. $VIRSeptember 1, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Gap Up Following Analyst UpgradeAugust 29, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Rating Increased to Buy at Bank of AmericaAugust 29, 2025 | marketbeat.comVir Biotechnology stock soars after BofA upgrade, $14 targetAugust 28, 2025 | investing.comVir Stock Soars After BofA Boosts Rating on Liver TherapyAugust 28, 2025 | finance.yahoo.comVir upgraded at BoA on potential for liver disease asset; shares surge 13%August 28, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025New Age Warfare: Anduril Is the Hype, AeroVironment Is the BuyBy Jeffrey Neal Johnson | August 28, 2025Take the Money and Run: Strategy Stock Looks Tapped OutBy Gabriel Osorio-Mazilli | September 9, 2025AeroVironment Is a Hot Buy With a Double-Digit UpsideBy Thomas Hughes | September 11, 2025NLTX, VIR, BGM, and SANA Company DescriptionsBGM Group NASDAQ:BGM$8.21 +0.35 (+4.45%) Closing price 04:00 PM EasternExtended Trading$8.40 +0.18 (+2.25%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Neoleukin Therapeutics NASDAQ:NLTX$19.00 -1.08 (-5.38%) As of 09/12/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Sana Biotechnology NASDAQ:SANA$3.10 -0.13 (-4.02%) Closing price 04:00 PM EasternExtended Trading$3.11 +0.01 (+0.45%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Vir Biotechnology NASDAQ:VIR$4.86 +0.07 (+1.46%) Closing price 04:00 PM EasternExtended Trading$4.86 0.00 (0.00%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
